Oxford BioMedica wins second $100 million gene therapy contract

LONDON (Reuters) - Britain's Oxford BioMedica has won a second $100 million contract to supply gene therapy material, this time from Bioverativ, which agreed last month to be acquired by Sanofi for $11.6 billion.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news